LATEST NEWS

ANVISA adds 33 products to the list of exempted healthcare products

Date: 10/22/2020

ANVISA published, on the 9th of October, Technical Note nº 218/2020 updating the list of products that are exempt from regulation by the Agency. Some of these products were included in the list of low risk health products (class I) subject to registration. However, considering that they did not fit the definition of medical devices according to RDC nº 185/2001, and ANVISA reported constant questioning about the proper classification of those devices, they have been removed.

According to Resolution No. 185/ 2001, a medical device is a health equipment, apparatus, material, or system of medical, dental or laboratory use, designed for the prevention, diagnosis, treatment, rehabilitation or conception and which do not uses pharmacological, immunological or metabolic means to perform its main function in human beings but can be assisted in their functions by such means.

Therefore, ANVISA included 33 new items to the list, and informed that those which had been previously registered will be cancelled. Some of the products are:

  • Pliers and scissors for cutting nails;
  • Wheelchair cushions, except for ulcer prevention;
  • Bib for dental use;
  • Trays / Boxes / Cases, including for sterilization (Labels to identify boxes / racks);
  • Pen for surgical marking;
  • Device that destroys and disables a medical device / counter (needles, scalpels, and others);
  • Packaging for sterilizing medical products;
  • Organ transport and storage packaging;
  • Canvas / device / field for patient transfer;
  • Gloves with no indication of health use;
  • Nipple protector;
  • Patient identification bracelets (including mother-child bracelets) and risk classification bracelets,
  • Restrictors used to contain the patient;
  • Disposable hospital bedding;

The full list contains 9 categories of products and is available here.

Follow us on social media to get an update on the top news regarding the Brazilian regulatory system.

DOMO Salute Team

MORE NEWS

07/18/2024
  From June 24 to 28, ANVISA participated in the MDSAP Forum and Regulatory Authority Council (RAC) meeting in Essen, Germany. The event gathered representatives from 27 countries, including regulatory authorities, MDSAP auditing organizations, and industry representatives, with notable attendance from Brazilian associations ABIMED and [...]
07/02/2024
  In force since January 2022, RDC 591/2021, which provides for the Unique Device Identification (UDI) system, was amended by ANVISA just days before the deadline for attributing and affixing UDI to risk class IV devices. The amendment was published in RDC 884/2024 on June 1, 2024, and is already in force. According to ANVISA,... Leia [...]
04/12/2024
Marking a significant advancement in regulatory reliance mechanisms, the National Health Surveillance Agency (ANVISA) published Normative Instruction (IN) 290/2024, on April 8, 2024. This normative introduces an optimized procedure for evaluating and deciding on registration petitions for medical devices previously regulated in recognized [...]
03/22/2024
Important Regulatory Update for Manufacturers under MDSAP in Brazil Today, ANVISA has announced a significant regulatory development with the publication of Resolution RDC 850/2024. This regulation brings forth a crucial amendment concerning the validity period of the Brazilian Good Manufacturing Practices (BGMP) Certificate for manufacturers [...]
01/05/2024
Collegiate Board Resolution (RDC) 837/2023, published by ANVISA on December 15th, 2023, brings updates to the rules regarding clinical investigations with medical devices performed in Brazil. Effective immediately from the publication, this resolution aligns Brazilian practices with international standards, providing clearer guidelines for [...]
12/13/2023
On 11 of December 2023, ANVISA published Collegiate Board Resolution – RDC 830/2023, addressing risk classification, registration procedures, as well as labeling requirements and instructions for use of in vitro diagnostic medical devices (IVDs) in Brazil. The new RDC, effective from June 1, 2024, is a comprehensive revision that consolidates [...]
11/28/2023
Public Consultation No. 1.208 will be open to receive contributions until December 9th. In the dynamic landscape of medical device regulations in Brazil, obtaining the Brazilian Good Manufacturing Practices (BGMP) certification is a mandatory request for manufacturers of Class III and Class IV devices seeking Registro. In a recent move towards [...]
03/01/2023
  Starting today – March 1st 2023 – the new Resolution RDC nº 751/2022  comes into force. The Resolution provides for risk classification, Notification and Registro processes, and the requirements for medical devices’ labeling and instructions for use. In order to meet the new requirements and procedures, ANVISA has already [...]
09/22/2022
The Collegiate Board Resolution – RDC 751/2022 was published on the 21st of September 2022, which provides for risk classification, Notification and Registro processes, and the requirements for medical devices’ labeling and instructions for use. The new RDC consolidates the risk classification and regularization regimes for all risk [...]